EMA Authorised: Herwenda (trastuzumab) — Sandoz GmbH

View source ↗

Summary

Authorised trastuzumab product Herwenda by Sandoz GmbH for breast and stomach neoplasms in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Stomach Neoplasms

Drugs mentioned

• Herwenda (trastuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Stomach Neoplasms. MAH: Sandoz GmbH. Decision date: 09/07/2026